Updates
** Drug developer Mineralys Therapeutics' MLYS.O shares rise as much as 73% to a near two-year high of $18.19
** Stock set for biggest percentage gain in a day on record
** MLYS says its experimental drug, lorundrostat, met the main goals of mid- and late-stage trials
** In the late-stage trial, co's drug reduced blood pressure by 9.1 mmHg (millimeters of mercury) at 6 weeks, compared with placebo
** Lorundrostat inhibits production of aldosterone, a hormone that can contribute to high blood pressure
** In the mid-stage trial, the drug reduced blood pressure by placebo-adjusted 7.9 mmHg
** Brokerage Guggenheim hailed the data as a major win for the drug, saying it could become a "potent first-in-class and (a) potential best-in-class agent"
** Stock has fallen 24.7% in the last 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.